Nivolumab combined with AVD demonstrated superior progression-free survival compared with brentuximab vedotin with AVD in advanced classical Hodgkin lymphoma (cHL). The SWOG S1826 trial showed a ...
Background: Renal ischemia-reperfusion injury (RIRI) represents a leading cause of acute kidney injury (AKI). Mitochondria, serving as the central organelles for cellular energy metabolism and signal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback